Bristol Myers Squibb CO Form 4 insider transactions

Director Phyllis Yale reports the acquisition of deferred share units convertible to common stock of Bristol-Myers Squibb.

Director Karen H. Vousden reports acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon cessation of directorship or at a specified future date.

Theodore R. Samuels II, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, convertible to common stock upon settlement.

Director Derica W. Rice acquired 3,562.431 deferred share units of Bristol-Myers Squibb on February 1, 2025, convertible to common stock upon ceasing to be a director or at a previously specified future date.

Director Paula A. Price reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Michael R. McMullen, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, convertible to common stock upon settlement.

Director Manuel Hidalgo Medina acquired 3,562.341 deferred share units of Bristol-Myers Squibb on February 1, 2025.

Julia Haller, a director of Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, at a price of $58.95 per unit.

Deepak Bhatt, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, convertible to common stock upon settlement.

Director Peter Arduini reports the acquisition of deferred share units in Bristol-Myers Squibb, convertible to common stock upon future settlement.

Benjamin Hickey, President of RayzeBio Org. and an officer of Bristol-Myers Squibb, reports the vesting of restricted stock units and subsequent tax withholding.

Gregory Scott Meyers, EVP, Chief Digital & Tech Officer at Bristol-Myers Squibb, reports the vesting of restricted stock units and subsequent tax withholding.

Director Phyllis Yale acquired 618.812 deferred share units of Bristol-Myers Squibb on December 31, 2024, convertible to common stock upon settlement.

Director Theodore R. Samuels II acquired 884.017 deferred share units of Bristol-Myers Squibb on December 31, 2024, convertible to common stock upon settlement.

Director Derica W. Rice acquired 663.013 deferred share units of Bristol-Myers Squibb on December 31, 2024, which will convert to common stock upon settlement.

Director Michael R. McMullen acquired 552.511 deferred share units of Bristol-Myers Squibb on December 31, 2024.

Peter J. Arduini, a director at Bristol-Myers Squibb, acquired 596.711 deferred share units on December 31, 2024, convertible to common stock upon his departure as a director or at a previously specified date.

Phil M. Holzer, SVP and Controller at Bristol-Myers Squibb, reported the sale of 700 shares of common stock on November 4, 2024.

EVP Karin Shanahan reports acquisition of restricted stock units and adjustments to common stock holdings through a 401(k) plan.

Gregory Scott Meyers, EVP, Chief Digital & Tech Off. of Bristol-Myers Squibb, reports acquisition of restricted stock units.

Christopher Boerner, CEO of Bristol-Myers Squibb, reports the vesting and disposal of market share units and shares for tax obligations.

EVP, Chief Medical Officer, Drug Development at Bristol-Myers Squibb, Samit Hirawat, purchased 1,830 shares of BMY stock at $54.675 per share on November 1, 2024.

EVP Cari Gallman reports acquisition and disposal of Bristol-Myers Squibb common stock and restricted stock units.

Director Phyllis Yale reports acquisition of deferred share units convertible to common stock in Bristol-Myers Squibb.

Director Theodore R. Samuels II acquired 966.37 deferred share units of Bristol-Myers Squibb on September 30, 2024, at a price of $51.74 per unit.

Director Derica W. Rice reports acquiring deferred share units convertible to common stock in Bristol-Myers Squibb.

Michael R. McMullen, a director at Bristol-Myers Squibb, acquired deferred share units convertible to common stock on September 30, 2024.

Director Deepak Bhatt acquired deferred share units convertible to common stock in Bristol-Myers Squibb on September 30, 2024.

Peter J. Arduini, a director of Bristol-Myers Squibb, acquired deferred share units convertible to common stock on September 30, 2024.

EVP Cari Gallman reports the vesting of restricted stock units and subsequent tax withholding of shares.